Urinary Incontinence - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Urinary Incontinence - Pipeline Review, H2 2016

Urinary Incontinence - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Urinary Incontinence - Pipeline Review, H2 2016
Published Jul 13, 2016
81 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Urinary Incontinence - Pipeline Review, H2 2016, provides an overview of the Urinary Incontinence pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence
- The report reviews pipeline therapeutics for Urinary Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Urinary Incontinence therapeutics and enlists all their major and minor projects
- The report assesses Urinary Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Urinary Incontinence

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline

  
Source:
Document ID
GMDHC8272IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Urinary Incontinence Overview81
Therapeutics Development92
  Pipeline Products for Urinary Incontinence Overview91
  Pipeline Products for Urinary Incontinence Comparative Analysis101
Urinary Incontinence Therapeutics under Development by Companies111
Urinary Incontinence Therapeutics under Investigation by Universities/Institutes121
Urinary Incontinence Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Urinary Incontinence Products under Development by Companies161
Urinary Incontinence Products under Investigation by Universities/Institutes171
Urinary Incontinence Companies Involved in Therapeutics Development1811
  Astellas Pharma Inc.181
  Celogos191
  Cook MyoSite Incorporated201
  FemmePharma Global Healthcare, Inc.211
  GTx, Inc.221
  Innovacell Biotechnologie AG231
  Ipsen S.A.241
  Outpost Medicine Limited251
  Taiho Pharmaceutical Co., Ltd.261
  Takeda Pharmaceutical Company Limited271
  TheraVida, Inc.281
Urinary Incontinence Therapeutics Assessment2910
  Assessment by Monotherapy Products291
  Assessment by Combination Products301
  Assessment by Target312
  Assessment by Mechanism of Action332
  Assessment by Route of Administration352
  Assessment by Molecule Type372
Drug Profiles3927
  (mirabegron + solifenacin succinate) Drug Profile392
  abobotulinumtoxin A Drug Profile414
  ASP-2205 Drug Profile451
  Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases Drug Profile461
  Cell Therapy for Urinary Incontinence Drug Profile471
  enobosarm Drug Profile487
  Gtx-027 Drug Profile551
  ICES-13 Drug Profile561
  OP-233 Drug Profile571
  oxybutynin chloride Drug Profile581
  Prof-003 Drug Profile591
  RCD-1 Drug Profile601
  Small Molecule to Inhibit NET for Stress Urinary Incontinence Drug Profile611
  TAS-303 Drug Profile621
  THVD-201 Drug Profile632
  THVD-202 Drug Profile651
Urinary Incontinence Dormant Projects663
Urinary Incontinence Discontinued Products692
Urinary Incontinence Product Development Milestones719
  Featured News &Press Releases711
    Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting711
    Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting711
    Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence721
    Oct 13, 2015: GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence721
    May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial731
    Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg741
    Jan 03, 2013: TheraVida Announces Positive Top-line Phase II Results For Tolenix In Patients With Overactive Bladder And Urge Urinary Incontinence741
    Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference751
    Dec 05, 2011: Pfizer s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients751
    Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency761
    Aug 30, 2011: Innovacell passes a further milestone761
    May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence771
    Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201781
    Feb 22, 2011: Innovacell makes further progress on product development781
    Jun 28, 2010: Astellas and Teva reached a Settlement Agreement on VESIcare Patent Case791
Appendix802
  Methodology801
  Coverage801
  Secondary Research801
  Primary Research801
  Expert Panel Validation801
  Contact Us801
  Disclaimer811

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Urinary Incontinence - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Urinary-Incontinence-Pipeline-Review-H2-2016-2088-16173>
  
APA:
Global Markets Direct - Market Research. (2016). Urinary Incontinence - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Urinary-Incontinence-Pipeline-Review-H2-2016-2088-16173>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.